AcelRx will issue 6.6 million shares at up to $14 each to raise $92.9m, including 865,500 shares the investment bank Piper Jaffray can sell if demand is strong enough. After the initial public offering (IPO), AcelRx will have a market capitalisation of up to $230m based on 16.1 million shares in issuance.

AcelRx Pharmaceuticals, a US-based developer of pain therapies formerly known as SuRx Pharmaceuticals, has revised its regulatory filing ahead of its planned flotation on the Nasdaq stock exchange.

AcelRx will issue 6.6 million shares at up to $14 each to raise $92.9m, including 865,500 shares the investment bank Piper Jaffray can sell if demand is strong enough. After the initial public offering (IPO), AcelRx will have a market capitalisation of up to $230m based on 16.1 million shares in issuance.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?